{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:41:27Z","timestamp":1791477687729,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005199","name":"Chinese Medicine Research Program of Zhejiang Province","doi-asserted-by":"publisher","award":["2016ZB004"],"award-info":[{"award-number":["2016ZB004"]}],"id":[{"id":"10.13039\/501100005199","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005199","name":"Chinese Medicine Research Program of Zhejiang Province","doi-asserted-by":"publisher","award":["2019ZA024"],"award-info":[{"award-number":["2019ZA024"]}],"id":[{"id":"10.13039\/501100005199","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Medical Health Science and Technology Project of Zhejiang Provincial Health Commission","award":["2018KY322"],"award-info":[{"award-number":["2018KY322"]}]},{"name":"the Program of Zhejiang Province Natural Science Foundation","award":["LY17H290007"],"award-info":[{"award-number":["LY17H290007"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nonalcoholic fatty liver disease (NAFLD) has become the most common liver disease worldwide. Recent studies have shown that the Angptl2 pathway mediated hepatic inflammatory response plays an important role in the progression of nonalcoholic fatty liver disease. Our study investigated the possible molecular mechanisms of berberine (BBR) in the treatment of the liver inflammatory response in the livers of rats with high-fat diet-induced NAFLD via the Angptl2 pathway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At the end of 12\u2009weeks, compared with the control group rats, the high-fat- diet group rats showed obvious pathological and biochemical changes. The levels of pro-infalmmatory cytokines (CCL2, TNF-\u03b1) were increased, the infiltration of inflammatory cells (CCR2) was elevated, and the hepatic mRNA and protein levels of Angptl2, NF-\u03baB and Foxo1 were increased to different degrees. Nevertheless, following treatment with BBR, liver tissue pathology, biochemical data, and Angptl2 pathway-related genes expression were significantly ameliorated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings demonstrate that BBR might attenuate the liver inflammatory response in the livers of rats with high-fat diet-induced NAFLD through the regulation of the Angptl2 pathway.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12865-020-00358-9","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T06:03:21Z","timestamp":1589868201000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Anti-inflammatory activity of berberine in non-alcoholic fatty liver disease via the Angptl2 pathway"],"prefix":"10.1186","volume":"21","author":[{"given":"Zengsheng","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beihui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoxiang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9832-397X","authenticated-orcid":false,"given":"Liyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,19]]},"reference":[{"issue":"Suppl 1","key":"358_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/liv.13301","volume":"37","author":"P Bedossa","year":"2017","unstructured":"Bedossa P. Pathology of non-alcoholic fatty liver disease. Liver Int. 2017;37(Suppl 1):85\u20139.","journal-title":"Liver Int"},{"key":"358_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"358_CR3","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jhep.2008.10.010","volume":"50","author":"JG Fan","year":"2009","unstructured":"Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol. 2009;50:204\u201310.","journal-title":"J Hepatol"},{"key":"358_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nature13478","volume":"510","author":"RJ Perry","year":"2014","unstructured":"Perry RJ, Samuel VT, Petersen KF, Shulman GI. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature. 2014;510:84\u201391.","journal-title":"Nature."},{"key":"358_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.clinre.2016.07.005","volume":"41","author":"N Motamed","year":"2017","unstructured":"Motamed N, Rabiee B, Poustchi H, Dehestani B, Hemasi GR, Khonsari MR, et al. Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases. Clin Res Hepatol Gastroenterol. 2017;41:31\u20138.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"358_CR6","doi-asserted-by":"publisher","first-page":"A23","DOI":"10.1136\/gutjnl-2013-305143.53","volume":"62","author":"P Basu","year":"2013","unstructured":"Basu P, Shah NJ, Farhat S, Siriki R, Mittimanj K, Atluri S, et al. Curcumin, anti-oxidant, and pioglitazone therapy with inclusion of vitamin E in non alcoholic fatty liver disease-a randomized open label placebo controlled clinical prospective trial (captive). Gut. 2013;62:A23.","journal-title":"Gut."},{"key":"358_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.cct.2008.09.003","volume":"30","author":"NP Chalasani","year":"2009","unstructured":"Chalasani NP, Sanyal AJ, Kowdley KV, Robuck PR, Hoofnagle J, Kleiner DE, et al. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials. 2009;30:88\u201396.","journal-title":"Contemp Clin Trials"},{"key":"358_CR8","doi-asserted-by":"publisher","first-page":"S507","DOI":"10.1016\/S0168-8278(12)61297-5","volume":"56","author":"AJ Haidarlo","year":"2012","unstructured":"Haidarlo AJ, Rashidbeygi M, Ehsanbakhsh S. Vitamin E, pioglitazone and diet therapy for patients with nonalcoholic fatty liver disease (Nafld): evaluation of treatment. J Hepatol. 2012;56:S507.","journal-title":"J Hepatol"},{"key":"358_CR9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1159\/000356535","volume":"21","author":"J Lasselin","year":"2014","unstructured":"Lasselin J, Capuron L. Chronic low-grade inflammation in metabolic disorders: relevance for behavioral symptoms. Neuroimmunomodulation. 2014;21:95\u2013101.","journal-title":"Neuroimmunomodulation."},{"key":"358_CR10","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1172\/JCI26498","volume":"116","author":"H Kanda","year":"2006","unstructured":"Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Investig. 2006;116:1494\u2013505.","journal-title":"J Clin Investig"},{"key":"358_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1172\/JCI24335","volume":"116","author":"SP Weisberg","year":"2006","unstructured":"Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Investig. 2006;116:115\u201324.","journal-title":"J Clin Investig"},{"key":"358_CR12","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1517\/13543784.2010.517745","volume":"19","author":"PR Vuddanda","year":"2010","unstructured":"Vuddanda PR, Chakraborty S, Singh S. Berberine: a potential phytochemical with multispectrum therapeutic activities. Expert Opin Investig Drugs. 2010;19:1297\u2013307.","journal-title":"Expert Opin Investig Drugs"},{"key":"358_CR13","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1111\/jcmm.12119","volume":"17","author":"J Zhang","year":"2013","unstructured":"Zhang J, Cao H, Zhang B, Cao H, Xu X, Ruan H, et al. Berberine potently attenuates intestinal polyps growth in ApcMin mice and familial adenomatous polyposis patients through inhibition of Wnt signalling. J Cell Mol Med. 2013;17:1484\u201393.","journal-title":"J Cell Mol Med"},{"key":"358_CR14","first-page":"308134","volume":"2013","author":"Y Liu","year":"2013","unstructured":"Liu Y, Zhang L, Song H, Ji G. Update on berberine in nonalcoholic fatty liver disease. Evid Based Complement Alternat Med. 2013;2013:308134.","journal-title":"Evid Based Complement Alternat Med"},{"key":"358_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12967-015-0383-6","volume":"13","author":"X Yuan","year":"2015","unstructured":"Yuan X, Wang J, Tang X, Li Y, Xia P, Gao X, et al. Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles. J Transl Med. 2015;13:24.","journal-title":"J Transl Med"},{"key":"358_CR16","first-page":"10","volume":"21","author":"X Zhu","year":"2016","unstructured":"Zhu X, Bian H, Gao X. The potential mechanisms of Berberine in the treatment of nonalcoholic fatty liver disease. Molecules. 2016;21:10.","journal-title":"Molecules."},{"key":"358_CR17","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.cmet.2009.08.003","volume":"10","author":"M Tabata","year":"2009","unstructured":"Tabata M, Kadomatsu T, Fukuhara S, Miyata K, Ito Y, Endo M, et al. Angiopoietin- like protein 2 promotes chronic adipose tissue inflammation and obesity- related systemic insulin resistance. Cell Metab. 2009;10:178\u201388.","journal-title":"Cell Metab"},{"key":"358_CR18","doi-asserted-by":"publisher","first-page":"ra7","DOI":"10.1126\/scisignal.2004612","volume":"7","author":"H Odagiri","year":"2014","unstructured":"Odagiri H, Kadomatsu T, Endo M, Masuda T, Morioka MS, Fukuhara S, et al. The secreted protein ANGPTL2 promotes metastasis of osteosarcoma cells through integrin alpha5beta1, p38 MAPK, and matrix metalloproteinases. Sci Signal. 2014;7:ra7.","journal-title":"Sci Signal"},{"key":"358_CR19","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1161\/ATVBAHA.113.303116","volume":"34","author":"E Horio","year":"2014","unstructured":"Horio E, Kadomatsu T, Miyata K, Arai Y, Hosokawa K, Doi Y, et al. Role of endothelial cell-derived angptl2 in vascular inflammation leading to endothelial dysfunction and atherosclerosis progression. Arterioscler Thromb Vasc Biol. 2014;34:790\u2013800.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"358_CR20","doi-asserted-by":"publisher","first-page":"7502","DOI":"10.1158\/0008-5472.CAN-11-1758","volume":"71","author":"J Aoi","year":"2011","unstructured":"Aoi J, Endo M, Kadomatsu T, Miyata K, Nakano M, Horiguchi H, et al. Angiopoietin-like protein 2 is an important facilitator of inflammatory carcinogenesis and metastasis. Cancer Res. 2011;71:7502\u201312.","journal-title":"Cancer Res"},{"key":"358_CR21","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nrgastro.2013.183","volume":"10","author":"GA Michelotti","year":"2013","unstructured":"Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013;10:656\u201365.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"358_CR22","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","volume":"114","author":"CP Day","year":"1998","unstructured":"Day CP, James OFW. Steatohepatitis: a tale of two \u201chits\u201d? Gastroenterology. 1998;114:842\u20135.","journal-title":"Gastroenterology."},{"key":"358_CR23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.mce.2011.04.002","volume":"339","author":"JY Zheng","year":"2011","unstructured":"Zheng JY, Zou JJ, Wang WZ, Feng XY, Shi YY, Zhao Y, et al. Tumor necrosis factor-alpha increases angiopoietin-like protein 2 gene expression by activating Foxo1 in 3T3-L1 adipocytes. Mol Cell Endocrinol. 2011;339:120\u20139.","journal-title":"Mol Cell Endocrinol"},{"key":"358_CR24","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.tem.2014.03.012","volume":"25","author":"T Kadomatsu","year":"2014","unstructured":"Kadomatsu T, Endo M, Miyata K, Oike Y. Diverse roles of ANGPTL2 in physiology and pathophysiology. Trends Endocrinol Metab. 2014;25:245\u201354.","journal-title":"Trends Endocrinol Metab"},{"key":"358_CR25","doi-asserted-by":"publisher","first-page":"e0131176","DOI":"10.1371\/journal.pone.0131176","volume":"10","author":"Y Sasaki","year":"2015","unstructured":"Sasaki Y, Ohta M, Desai D, Figueiredo JL, Whelan MC, Sugano T, et al. Angiopoietin like protein 2 (ANGPTL2) promotes adipose tissue macrophage and T lymphocyte accumulation and leads to insulin resistance. PLoS One. 2015;10:e0131176.","journal-title":"PLoS One"},{"key":"358_CR26","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.cell.2010.02.034","volume":"140","author":"GS Hotamisligil","year":"2010","unstructured":"Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell. 2010;140:900\u201317.","journal-title":"Cell."},{"key":"358_CR27","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.ejphar.2011.07.036","volume":"668","author":"LJ Xing","year":"2011","unstructured":"Xing LJ, Zhang L, Liu T, Hua YQ, Zheng PY, Ji G. Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver. Eur J Pharmacol. 2011;668:467\u201371.","journal-title":"Eur J Pharmacol"},{"key":"358_CR28","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.2337\/db07-1552","volume":"57","author":"N Turner","year":"2008","unstructured":"Turner N, Li JY, Gosby A, To SW, Cheng Z, Miyoshi H, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes. 2008;57:1414\u20138.","journal-title":"Diabetes."},{"key":"358_CR29","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.2337\/db14-1506","volume":"64","author":"JR Cook","year":"2015","unstructured":"Cook JR, Matsumoto M, Banks AS, Kitamura T, Tsuchiya K, Accili D, et al. A mutant allele encoding DNA binding-deficient FoxO1 differentially regulates hepatic glucose and lipid metabolism. Diabetes. 2015;64:1951\u201365.","journal-title":"Diabetes."},{"key":"358_CR30","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1038\/onc.2008.27","volume":"27","author":"KC Arden","year":"2008","unstructured":"Arden KC. FOXO animal models reveal a variety of diverse roles for FOXO transcription factors. Oncogene. 2008;27:2345\u201350.","journal-title":"Oncogene."},{"key":"358_CR31","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.2337\/db07-0714","volume":"57","author":"L Valenti","year":"2008","unstructured":"Valenti L, Rametta R, Dongiovanni P, Maggioni M, Fracanzan AL, Zappa M, et al. Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis. Diabetes. 2008;57:1355\u201362.","journal-title":"Diabetes."},{"key":"358_CR32","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.2337\/db09-0232","volume":"58","author":"D Su","year":"2009","unstructured":"Su D, Coudriet GM, Hyun Kim D, Lu Y, Perdomo G, Qu S, et al. FoxO1 links insulin resistance to proinflammatory cytokine IL-1beta production in macrophages. Diabetes. 2009;58:2624\u201333.","journal-title":"Diabetes."},{"key":"358_CR33","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/ajg.2012.217","volume":"107","author":"N Chalasani","year":"2012","unstructured":"Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association (vol 107, pg 811, 2012). Am J Gastroenterol. 2012;107:1598.","journal-title":"Am J Gastroenterol"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-020-00358-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-020-00358-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-020-00358-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T19:20:54Z","timestamp":1621365654000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/s12865-020-00358-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,19]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["358"],"URL":"https:\/\/doi.org\/10.1186\/s12865-020-00358-9","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,19]]},"assertion":[{"value":"4 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The experimental protocols were established according to the Declaration of Helsinki, and the experiments were approved by the Experimental Animal Ethics Committee of the Animal Use and Care Committee of Tongde Hospital of Zhejiang Provice, (Approval NO.:[2019]013).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}